GR1803

· Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for GR1803, covering 2025-04-27 to 2026-03-10. Get the full timeline:

Most recent: Clinical Trial Update: A Study of GR1803 in Systemic Lupus Erythematosus [Phase 1, Phase 2]